Search

Coloplast A-S (Class B)

Fermé

546.2 0.18

Résumé

Variation du prix de l'action

24h

Actuel

Min

541.2

Max

546.8

Chiffres clés

By Trading Economics

Revenu

-107M

805M

Ventes

28M

7B

P/E

Moyenne du Secteur

33.892

78.892

BPA

3.88

Rendement du dividende

4.2

Marge bénéficiaire

11.569

Employés

16,744

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.20%

2.38%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-14B

123B

Ouverture précédente

546.02

Clôture précédente

546.2

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 déc. 2025, 22:03 UTC

Principaux Mouvements du Marché

Mining Stocks Slip Near the End of Stellar Year

29 déc. 2025, 15:57 UTC

Principaux Mouvements du Marché

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 déc. 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 déc. 2025, 23:38 UTC

Acquisitions, Fusions, Rachats

Manus: Will Continue to Operate From Singapore

29 déc. 2025, 23:38 UTC

Acquisitions, Fusions, Rachats

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 déc. 2025, 23:37 UTC

Acquisitions, Fusions, Rachats

Meta Platforms: Will Integrate Manus Service Into Products

29 déc. 2025, 23:36 UTC

Acquisitions, Fusions, Rachats

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 déc. 2025, 23:36 UTC

Acquisitions, Fusions, Rachats

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 déc. 2025, 23:35 UTC

Acquisitions, Fusions, Rachats

Manus to Join Meta Platforms

29 déc. 2025, 21:33 UTC

Acquisitions, Fusions, Rachats

Origin: Raise Values Kraken at US$8.65 Billion

29 déc. 2025, 21:33 UTC

Acquisitions, Fusions, Rachats

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 déc. 2025, 21:31 UTC

Acquisitions, Fusions, Rachats

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 déc. 2025, 21:31 UTC

Acquisitions, Fusions, Rachats

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 déc. 2025, 21:30 UTC

Acquisitions, Fusions, Rachats

Origin's Kraken Stake to Remain at 22.7%

29 déc. 2025, 21:30 UTC

Acquisitions, Fusions, Rachats

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 déc. 2025, 21:30 UTC

Acquisitions, Fusions, Rachats

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 déc. 2025, 21:30 UTC

Acquisitions, Fusions, Rachats

Origin: Additional Interest Offsets Dilution From Raise

29 déc. 2025, 21:30 UTC

Acquisitions, Fusions, Rachats

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 déc. 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 déc. 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 déc. 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 déc. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 déc. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 déc. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 déc. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 déc. 2025, 21:27 UTC

Acquisitions, Fusions, Rachats

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 déc. 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 déc. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 déc. 2025, 20:02 UTC

Acquisitions, Fusions, Rachats

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 déc. 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat